Eight years. Tens of millions of dollars. Not one unit sold. That is what it took Cody Simmons and his team to get DermaSensor through the FDA, the first automated skin cancer detection device cleared for primary care doctors. And the first three people on the team are still working together nine years later. Cody is the co-founder and CEO of DermaSensor. Time named it one of the best inventions of 2024, and it landed on Inc's list alongside Anthropic and NVIDIA. He did his graduate work in bioengineering at Stanford and spent four years at Genentech before joining his co-founder, a serial medical device entrepreneur, to turn a research technology into a company. Skin cancer is the cancer you can see, and yet only about eight percent of the hundred million Americans at risk get the recommended annual skin exam. I know why people avoid it. I sat on a mole for a long time because I did not want to hear the answer. So we walked through the four things every founder building something hard runs into: regulation, capital, trust and scale. And Cody told me about the second patient ever scanned after clearance, a man who was sure his mole was fine. It came back a 10 out of 10. What we get into: Why they went after family doctors instead of dermatologists From a microwave-sized desktop system to a one pound handheld Healthcare, hardware and the FDA, all at once How you hold a team together for eight years with no revenue Raising capital for something you are not allowed to sell yet The real objection: why not just use a photo and an algorithm A live demo, and how the device reads up to a millimeter beneath the surface of the skin Earning trust from people with far more training than you Not cutting corners on clinical data, and the pulse oximetry problem What broke first when they were finally cleared to sell Why Cody is now glad clearance did not come in 2023 300,000 primary care physicians at 140,000 locations, and why a small team cannot do it alone Timestamps 00:00 Meet Cody Simmons and DermaSensor 01:27 The founding story 03:39 From a microwave-sized machine to a one pound handheld 04:31 Why family doctors, not dermatologists 06:35 What primary care doctors miss 08:34 The mole I did not want to look at 10:18 The second patient ever scanned 12:00 Zooming out: regulation, capital, trust, scale 14:36 Eight years of R&D before selling unit one 16:56 The three people who stayed nine years 18:39 Raising money for something you cannot sell yet 21:49 Why not just a photo and an algorithm 23:22 Live demo of the device 26:33 Five tissue samples and the risk scale 28:27 Earning trust from people with more training than you 31:43 The pulse oximetry problem and what the FDA asked for 34:17 What broke first at launch 35:39 Why the timing worked out better 36:18 Scaling to 300,000 physicians 39:19 How to reach Cody About the guest Cody Simmons is the co-founder and CEO of DermaSensor, the first automated skin cancer detection device cleared by the FDA for primary care doctors. Stanford bioengineering, four years at Genentech, and ten years into building DermaSensor. He is responsive on LinkedIn. DermaSensor: https://www.dermasensor.com/ LinkedIn: https://www.linkedin.com/in/codyvsimmons/ Want to be a guest? We are looking for real operators, not celebrities. Fill out the guest form at the link below: https://forms.gle/guCp7wDBoUjkX86t7
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Gary Kadi: Hello and welcome back. Gary Cady here at the Delegate Podcast. I got a good one for you today. My guest today is Cody Simmons, co-founder and CEO of Dermosensor. Cody, we're so glad you're here. A guy who can spend eight years building the first automated skin cancer detection device cleared by the FDA for primary care doctors. It gives the answer in under 30 seconds. Time. called it one of the best in inventions in twenty twenty four and
in twenty twenty five Inc. magazine, the most innovative invention, right? Cody welcome. Cody Simmons: Yeah, we're we're on the list alongside Anthropic and NVIDIA actually, which was was really cool. Gary Kadi: Yeah. Cody Simmons: Yeah, when I when I saw that, you know, you know you're gonna get the award ahead of time, but you don't know who else is. So yeah, no, it was Gary Kadi: Right. Yeah. Cody Simmons: quite an honor. We we don't belong there from a valuation standpoint, but it was innovative technology. So I I think we we certainly hold our Gary Kadi: A I you're certainly a humble man. I mean, you you know, it's it's pretty cool. Thirty under thirty Forbes too, my man. I mean, goodness gracious.
Cody Simmons: Yeah, it was a it was a long time ago, but thank you. Gary Kadi: Yeah, well y I mean you couldn't tell by the way you Cody Simmons: I try, yeah. When you work in dermatology, you know, you gotta and live in Miami, Gary Kadi: take care of yourself, so you're doing pretty darn good. Cody Simmons: you gotta gotta try keeping youthful look. Gary Kadi: By the way, was is that by accident? I was when I was looking at my notes, I'm like he's doing dermosensor and he's in Miami. Was that was that by design or was that Okay. Cody Simmons: It's just coincidence. Nah, yeah. Well, so so yeah, as a bit of an interesting founding story, you know,
we're a bit unique actually, because so my co-founder, Dr. Maurice Foray, very successful serial medical device entrepreneur and executive. so he came across this technology. He's been on the board of trustees for I think 20 plus years. It's where he went to medical school at Boston University. so the spectroscopy technology was developed out of BU. And Gary Kadi: Nice. Cody Simmons: so actually they formed the company. I was still an undergrad. but then several years later, so there was never kind of any full-time employees, or you know, it's kind of some early data collection, almost think of it like a a
privately funded SBIR grant, right? Kind of early academic exploratory work. Gary Kadi: Right. Cody Simmons: and so, you know, and I did my graduate work in in bioengineering at Stanford and then was at Genentech for four years, mostly focused on oncology. And then it was head of business development at a similar startup that was doing had kind of screening and monitoring tools for frontline providers and patients at home. And a good friend of mine from college, he was actually my 20 years ago, my TA in an entrepreneurship class.
Gary Kadi: Hmm. Cody Simmons: ended up becoming good friends with them. And you we stayed in close touch. I actually lived with him the first year. I I lived in Miami a decade ago. so we were roommates for a year. He knew Maurice well. Maurice was an investor in his health tech fund here in Miami. And Gary Kadi: Mm-hmm. Cody Simmons: he's like, Hey, you gotta meet this guy. You know, I know you've had, you know, you've talked about how you've had skin biopsies. My first one, Gary, was as a teenager growing up playing tennis in Florida. So there's the Florida piece. Gary Kadi: I see. Cody Simmons: my mom and my aunt both had melanoma. Fortunately, early stage,
totally fine. So, you know, personally it was something I was very aware of and my family was very attuned to. Gary Kadi: Right. Cody Simmons: So, you know, I I kind of hats off to to my friend of the last 20 years, Christian Seal, who's like, wait, I know a big shot entrepreneur that has a skin can you know, cool skin cancer tech, and they're looking for someone to quote Maurice when I first spoke with them over 10 years ago. They're looking for someone to turn their research project into a company. Gary Kadi: Mm. Cody Simmons: So that's kind of where I got involved. We went from this,
you know, microwave size desktop spectroscopy system we built with BU. To this one pound handheld non-invasive device. Gary Kadi: Mm. Cody Simmons: and that was really the vision is okay, can you bring, you know, powerful diagnostic capabilities for skin cancer and put that in the hands of frontline providers, eventually patients at home, because skin cancer Gary Kadi: Mm-hmm. Cody Simmons: is the only cancer type you can always see, right? And that's really our focus. Let's let's avoid all Gary Kadi: Mm-hmm. Cody Simmons: deaths from the cancer that you can literally see, right?
Gary Kadi: Yeah. Cody Simmons: And so that's, you know, the focus and and really the approach in doing that. you know, there's been companies in the past that have really focused on dermatologists, but dermatologists by definition are specialized, are expert in dermatology. They're already Gary Kadi: Right. Cody Simmons: pretty good at dermatology. Go figure, right? Gary Kadi: Yep. Cody Simmons: of course, every expert and specialist can further improve their expertise and and but by and large, they're already pretty darn good at dermatology.
So the challenge the challenge though is only about eight percent of the hundred million Americans at risk for skin cancer actually get the recommended annual skin exam. So that's Gary Kadi: Right. Cody Simmons: the big challenge, is like someone like me that, you know, has family members that have had skin cancer, that has, you know, 80 to 100 plus moles on their body. if all of those people tried to go to dermatologist every year, they couldn't, right? There's already months Gary Kadi: Right. Cody Simmons: long wait times of many of them. And only Gary Kadi: Mm. Cody Simmons: around 10 million of the hundred million out-risk Americans actually get the recommended annual skin exam.
Gary Kadi: Mm. Cody Simmons: So that's what it's really a public health problem when you think about it, or like a dermatology Gary Kadi: Yeah. Cody Simmons: capacity problem, right? Like, okay, skin cancer Gary Kadi: Yeah. Cody Simmons: is visible, you can see it, but how do you actually effectively check it? So that's Gary Kadi: Right. Cody Simmons: that's the challenge we've been tackling. And we didn't come up with a solution in terms of the approach. So for decades, primary care, dermatology, public health are like, Let's just upskill non-dermatologists. But Gary Kadi: Right. Cody Simmons: by definition, non-dermatologists are not dermatologists and they didn't spend the
hundreds or thousands of hours training and assessing suspicious skin lesions and how to diagnose them, et cetera. And they don't have the time, you know, they're responsible for thousands of different diseases. They can't specialize in dermatology, right? Because they're not dermatologists. So Gary Kadi: Exactly. Yep. Cody Simmons: that was really our can we put the eyes of a dermatologist in the hands of hundreds of thousands of Frontline providers think family doctors, internists, OBGYNs, nurses at CBS Mediclinics, right? Pharmacists, anyone that a patient currently asks, or Gary, they could ask, Hey, what
Gary Kadi: Mm-hmm. Cody Simmons: do you think about this suspicious mole? Should I go see a dirt? Right? Like there's even news Gary Kadi: Right. Right. Cody Simmons: articles of like, hey, a hairstylist found the melanoma on my head. Right? Like there's crazy story. Gary Kadi: Inside. Yeah. Yeah. Cody Simmons: Yeah. And So, you know, our fur first focus is obviously physicians who currently already do this as part of their scope of practice. Right. Like when you ask your doctor, hey, what do you think about this mobile shy gooseoderm? They they can't really abstain, right? They can't be like, Gary Kadi: Right. Right. Cody Simmons: I I don't know, you decide on your own. It's like, wait, what?
You know, so it it's part of their scope of practice to make those decisions, but studies show they miss up to half of those cancers. And they're also doing, depending on what study you read, 20 to 40. Referrals or biopsies for every one melanoma. So, like only, you know, two to three percent of the referrals and biopsies they're doing for suspicion for melanoma are actually melanoma. So the other 90 Gary Kadi: Right. Cody Simmons: plus percent are unnecessary. So that's really where our big focus is you know, helping them detect more cancer and also avoiding unnecessary referrals and biopsies.
So that's a key thing to start with, right? Kind of better equipping. clinicians that are already doing skin checks to some degree. But then the kind of the next phase is how can we equip healthcare professionals and maybe eventually even patients at home that are not currently involved in doing skin checks, right? At least formally like Gary Kadi: Mm-hmm. Cody Simmons: pharmacists or aestheticians or even, you know, I don't know, barbers. You know, I I use that example because there are real stories about that. I don't know how the FDA Gary Kadi: Right. Cody Simmons: would ultimately feel about that. But yeah, that that, you know, examples of of kind
our philosophy in where we're Gary Kadi: Well, first of all, thank you for creating this because I think about all the peoples whose lives will be transformed because you took a research project and turned it into a company and now bringing it alive and having a solution for people to to address this. The gap between the actual number of people who have moles and and and suspicious items on their skin to the people that actually get it diagnosed. I know myself, I'm a sun worshiper. I love the sun and I had a mole right here. Cody Simmons: I was out to say, you you have a you have a good tan, but I wasn't gonna compliment
you. I was gonna give you some crap about that. I you I Gary Kadi: I no, no, and and appropriately so. Cody Simmons: used to have a good tan. Pre-derma sensor, I was all about having a a tan. Gary Kadi: Yeah. Yeah, no, I'm here on Cape Cod. So like, you know, beach is like, you know, my sec I'm in podcast room and I'm on the beach, you know, with my family. So, but I do wear sunscreen. It is a long summer here, but I do want to say, like, when when I had that mole, it was non-cancerous, but like I didn't want to confront it, Cody, right? I I know my own experience. Cody Simmons: Mm-hmm.
Gary Kadi: I didn't want to come face to face and have that answer, you know, and I happen to be at a Cody Simmons: Was it was it like kind of a fear or concern, or was it just you didn't have time, you didn't want to deal with going Gary Kadi: No, it was a fear. I didn't want the answer. Cody Simmons: to get a biopsy? It was a fear, yeah. Gary Kadi: I I, you know, lived and I'm I'm as you were sharing, I was living in my own experience of it. And my Cody Simmons: Yeah. Gary Kadi: I went in for I forgot a blood, I think it was a you had a blood draw and my my my primary care said, Hey, you should probably go look at that. You know, it does it looks Cody Simmons: Yeah, yeah. Gary Kadi: fine, but you should go look at it. And when I went
and yeah, they said let's take it off. you know, it's so You know, ever since then, I and and when I saw that we were going to talk today, I really looked at your website and did my research and really saw like I wasn't sure how you were approaching this, right? And I really love that you're really giving access to people to save people's lives that wouldn't normally have that access. But not only for the practitioner, Cody, what I'm experiencing and listening to is for the patient who, like me, was in avoidance about things.
Right, and wouldn't do my regular screening. Now I go every year because of that, but I really wanna acknowledge you for that, you know. Cody Simmons: Now you're good about it. Thank you. And and Gary, it's it's interesting you share that story because and and just wild statistically, but the second patient that was ever scanned with our device following FDA approval was exactly your profile. so Gary Kadi: Yeah. Yeah. Cody Simmons: I I don't know any identifiable information anyway, but it was an elderly, elderly Caucasian gentleman that the first user, Dr. Kevin Wong.
In Pennsylvania. he was the first person to have got a device in the US in May 2024. And he said his Gary Kadi: Hmm. Hmm. Cody Simmons: second patient, a couple of weeks after getting the device, his second patient, older guy, had some well, I think he said it was on his like upper torso. And he's like, Yeah, I've had it for a couple of years. I'm not worried about it, it's fine. And he's like, This really looks like a clear-cut case of melanoma. I'm worried about it. I want you to go see a dermatologist. And he's like, the guy was arguing with him. He's like, I don't
want to deal with that. I'm sure it's fine. I don't want Gary Kadi: Yeah. Cody Simmons: to go. And he's like, well, you know, good news is we just got this new device in literally two weeks ago. Let's go ahead and scan it. It gives a zero to 10 risk scale for skin cancer. And it was just approved by Gary Kadi: Yeah. Cody Simmons: the FDA. There's, you know, two published studies of the many studies show it's as accurate as in-person dermatologists. Let's go ahead and scan it. And the result was 10 out of 10. And which in Gary Kadi: Right. Cody Simmons: our pivotal study was a 61% chance of being cancer. Yeah. And so the doctor's like I was immediately not only
immediately able to convince him to go, but I also called up a local dermatologist who instead of a couple month wait time was able to see him a week later. And Gary Kadi: Mm, beautiful. Cody Simmons: it was yeah, and it was biopsy and diagnosed melanoma. So yeah. Gary Kadi: Well, amazing. So that's really where I'm sitting in. I'm sitting in this is a life changing device, but it it's a mission beyond that. but I want to zoom out for our entrepreneurs that are with us today, because that's our group, and I want to get into the entrepreneurial build of this thing and like into your world and sharing your experience.
And I'm gonna I'm gonna go over four areas. We're gonna talk about regulation, we're gonna talk about capital, we're gonna talk about trust, and we're gonna talk about scale. The first question is in inside of regulation. You know, you keep talking about FDA. I keep sitting here going, man, this poor guy. He was sitting there for eight years, tens of millions of bucks before he could sell unit one. How did you keep together a team that long with no revenue? and and keep the mission and mit and vision and and and and just everybody
taking steps forward to bring this to market. Let's let's zoom out and go there. Cody Simmons: Yep. Yeah, I mean I I think the healthcare is hard, hardware is hard, and dealing with the FDA or any major regulator is hard, right? People people commonly say each of those, and we did all three, right? Gary Kadi: Right. Cody Simmons: Healthcare, hardware, and FDA. So, you know, it's a very tough space. that being said, I think the big benefit that medical devices and biopharma, you know, as a genetic for a few years, have going for them.
And you know, for our device and and focus especially, is it's such an inspiring and engaging mission and vision, right? And Gary Kadi: Right. Cody Simmons: that's part of what drove me to it instead of finance, or you know, was certainly you can ultimately do well financially if you do well, sure, but you're also really bettering the world and impacting the world, right? And Gary Kadi: Right. Cody Simmons: you know, my my both my parents were kind of educators, and you know, that was always something I guess just innately we were kind of raised with is your job should align with
kind of your moral compass and kind of make making the world better. and so honestly I think it was kind of attracting like minded people to the company that understood, hey, this could end up being a long slog. May never even happen, right? A lot of academic researchers and even researchers within big pharma companies go their entire career without ever having worked on a drug that gets approved in patients, right? Some go their Gary Kadi: Right. Cody Simmons: their entire lives. and you know, you never know at the end
of that journey do you actually get FDA approval, right? So you know, roughly the eight years. So I'm 10 years in now, two years commercial, first eight years were R D. And so we started with that large device. If I was at my my office office versus my home office, it's it's behind me against the wall. So sorry you can't can't see it, but it's yeah, the idea was, you know, a year, year and a half to miniaturize it, maybe a couple years to run the study, and then a few month FDA approval process. So that was the hope in the beginning
be, you know, three years, maybe four years. Ended up three Gary Kadi: Yeah. Cody Simmons: years to miniaturize it, Gary Kadi: Wow. Cody Simmons: miniaturize it and kind of make the robust design to where it could be actually Gary Kadi: How big was it? Can you hold that up just so we can see so we can so that's the unit itself. Cody Simmons: So this is the current device. H yeah, here here's my smartphone for comparison, right? Here's my iPhone. So it's about the size of an iPhone. Yeah, kinda little. it's Gary Kadi: wow. Is that a is that a pro, a sixteen Cody Simmons: a air, yeah. So I think in between the Pro and the Gary Kadi: pro or something like that? It's pretty. Yeah. Yep. Cody Simmons: Max Plus or whatever the name of it. But yep. And so we yeah, so three years to miniaturize what was
a a microwave size or printer size. Yeah, it's it's actually a little bigger than that white printer in my bookshelf back there. Gary Kadi: Wow. Wow. Cody Simmons: so miniaturizing miniaturizing that to this. and we're talking with a big tech company and and some design firms about, hey, let's make a next gen device that's, you know, the size of a thick pen and can plug into the bottom of your phone. And, you know. So Gary Kadi: Right. Cody Simmons: yeah, so excited about kind of future miniaturization too. But so that took three years. Doing all the studies took four years, and
Gary Kadi: Mm. Cody Simmons: then the FDA approval process took one year. So that's kind of how they Gary Kadi: Oof. Man, you man, bless you for that, man. That is really strong leadership. And what I heard, the insight here I want to highlight for our entrepreneurs is really setting expectations with your employees. That's what I heard is the number one thing that that really made this work. You said, hey, this is gonna be a long slog, but it has a high purpose and a high impact. So you had the purpose in there, but you also had expectations. And I think that that's really important in the hiring process. So you've got somebody who really has a humanist root.
root in their in their soul, but they also know that this isn't gonna be like, you know, quick hits and likes on, you know, on social media. This is like, you know, you're gonna you're creating something for the for the future. And did you have someone Cody Simmons: Yeah. Gary Kadi: stay for for the eight years? Cody Simmons: There's three of us actually. So yeah, Gary Kadi: Great. Cody Simmons: our COO, Ryan Freedon, he joined eight months after I did. So brought him on. Cause the kind of founders are, you know, they're not too technical and I Gary Kadi: Yeah.
Cody Simmons: have a engineering background, but I never was an engineer. You know, so I Gary Kadi: I say Cody Simmons: but I, you know, know enough to talk shop with the real engineers. So Gary Kadi: Right. Cody Simmons: kind of got on board, started taking with engineers. I'm like, this is not gonna be one year. Like that this Gary Kadi: Yeah. Yeah. Cody Simmons: is not some quick and easy thing a as we were hoping it may be. So then I involved so Ryan's background had actually been involved in mechatronic, right? mechanical devices, electronic devices, miniaturization. He actually he probably wouldn't like me talking about it. He calls it his his claim to shame. He was his first startup, he's done like five before this, was one of the
first e-cigarette companies. And they were shipping tens of thousands of and he said as like, you know, we're as one of the first ones, like we actually did have noble intentions, which was to help avoid harmful smoking. You know, he didn't know what it would turn into ultimately. But Gary Kadi: Yeah. Cody Simmons: so yeah, he had been involved with some of the, you know, kind of high volume mechatronic kind of systems. So so he joined and knew a lot of software work. So he joined and then a couple months after him was our I
think at the time director, associate director of clinical operations, who now, nine years later, is our VP of clinical affairs, Justin Gary Kadi: Yep. Cody Simmons: Fraser. So yeah, kinda Gary Kadi: Yeah. Cody Simmons: us three we're the the first three team members have actually been working together now for over nine years. And and and along with all the Gary Kadi: congrats. Cody Simmons: board members, we've only added one new board director in the last nine years also. Gary Kadi: Awesome. So now I want to move to capital because I know you just got a capital Cody Simmons: Sure. Gary Kadi: raise. And I but I like getting behind the scenes, right? Here
you are, you have a version, a big monster version of this machine that really has a high, you know, clear value. But how do you raise money when something can't be legally sold yet? What I want to hear is like, what is the thing that wasn't in the debt for investors that like you created That had them say, Yes, we're gonna get behind this. I want I wanna really we like transparency and vulnerability if you're willing to go there and Yeah, Cody Simmons: understand how that works. Yeah. Gary Kadi: please.
Cody Simmons: Yeah. I mean, I I think a lot of it again, kind of back to you know, the the world of drugs and and devices is, you know, there's just a clear cut medical need. In our case, I mean, Gary, you're a perfect example. That just impacts so many people, right? One in five Americans get skin cancer Gary Kadi: Yeah. Yeah. Cody Simmons: by the age of 70. five year survival rate is 99% of detected early, 40% if detected at stage four. Gary Kadi: Mm, mm. Cody Simmons: So, you know, it's it's something that people I think can often kind of intuitively relate to. And like once so often when I tell people about our work
or I show people the device, they're like, that's so obvious. Like, why hasn't that existed before? That's such a great idea. And it's like, Gary Kadi: Yeah. Cody Simmons: well yeah, it's a great idea. It's very hard to do, right? Like flying cars is a great idea too. Good luck building them, right? So Gary Kadi: Right. Cody Simmons: you know, I think that was kind of for us very challenging. To actually build it and validate it and get through the FDA. And I'll talk to image-based tools in a minute. But I think just that intrinsic intrinsic, like this is something that should exist and will be successful. Right?
Gary Kadi: Basic time. Right. Cody Simmons: Like it may, you know, there may be setbacks on the way, commercially, you know, reimbursement or channel partners and you know, workflow, changing physician behavior, how's that all gonna pan out? But one of our new a great physician collaborator that I spoke with a month ago. He he he I think said it very aptly, which was this is going to be the new normal. Like we're Gary Kadi: Mm-hmm. Cody Simmons: gonna look back at how we at how we as primary care doctors used to check skin cancer and be like, man, that
Gary Kadi: Right. Cody Simmons: was so that was so primitive. Right? Like that that we used to just Gary Kadi: Yep. yeah, for sure. Yeah. Cody Simmons: eyeball something that could kill our patients, having no Gary Kadi: Yeah. Cody Simmons: ex having no expertise, like very limited training, no expertise, no specialty, and be like, nah, you're okay. Like He's like it's it it's just when you just think about where we will be, it's gonna be whether it's your tool, similar to what you know, this will be the new normal. And so I think that kind of having that clear sense of a vision and what the future holds
was definitely helpful. And you know, with there were tough tough honestly, Gary, in the early days the most challenging aspect wasn't even really selling that vision that like this is what the future will look like. It was actually selling that this technology will be the leader or one of the leaders for that future. Because Gary Kadi: Mm. Cody Simmons: articles had just been coming out. It was early, you know, seven, eight years ago, was the early medical imaging AI stuff. Right. So it's Gary Kadi: Right. Cody Simmons: way before Gen AI, but it was when a lot of the predictive diagnostics with
radiology and the first paper on applying algorithms to photos of skin lesions was thirty-five Gary Kadi: Yeah. Cody Simmons: years ago. Gary Kadi: Yeah. Cody Simmons: And then really started becoming more and more hot, you know, nine, nine, eight, nine years ago. Like publications went from okay, five or ten a year to like a hundred a year. So there's a lot of investors that are like, why are we underwriting miniaturizing this huge device that you have to deal with manufacturing issues and miniaturization and you know, supply chains, blah, blah, blah, when there's papers coming out saying you can just take a photo from your smartphone and run Gary Kadi: Right. Cody Simmons: AI algorithm and that it's as good or better than a dermatologist?
So that was Gary Kadi: Right. Cody Simmons: actually our our challenge in the early days. Now that's not so much our issue because all the there's an order of magnitude more publications, order of magnitude more companies using image-based approaches, and not a single Gary Kadi: Right. Cody Simmons: one is available in the US. they have to standardize lighting, distance, skin of color is an issue, hair in the way is an issue. And Gary, if you Gary Kadi: Mm. Cody Simmons: solve for all of that, great, you're just getting a photo of the surface of the skin that Gary Kadi: Right. Cody Simmons: the doctor's already looking at. Like Gary Kadi: Right.
Cody Simmons: Cool cool. Yeah, okay. You're Gary Kadi: It's more of the same. Cody Simmons: yeah, you're better analyzing the surface of the skin than the doctor's already looking at, great. But we're actually taking non invasive tissue samples up to a millimeter beneath the surface of the skin. Gary Kadi: wow. Cody Simmons: So that's kind of how our technology works. Yeah, I can do a demo or or can pop up a slide if Gary Kadi: Yeah, let's do a de let's do a quick demo real quick. I think it's good time for that. Cody Simmons: Yeah, so the device pulses in here. I'll so I'll act like I'm a doctor and my arm is the patient. And I'll go into a little more detail than you know a doctor normally would,
just cause, you know, to to share more more details here. But and I joke, I I was born for this job. I have a perfect demo mole right on my forearm. It's like five minutes, and it's funny actually, d dermatologists, not just PCPs, two dermatologists over the years that have been my dermatologist have wanted a biopsy. Like, it looks a little funky. Gary Kadi: wow, perfect. Yeah. Cody Simmons: And I'm like, you can't biopsy it. It's stayed the same for a decade, and I need it for my job. So you can't. Gary Kadi: Right. Cody Simmons: So I guess maybe I'm putting myself at a little
health risk for the company, but it it's worth it. Gary Kadi: All right, perfect. Cody Simmons: So yeah, so just a visual, right? Like I'm a family doctor, right? My arms me. So okay, Cody, you mentioned you're a little worried about this mole, maybe Gary Kadi: Yeah. Cody Simmons: that maybe it's you know, it's a little larger and different than the others. It it does Gary Kadi: Right. Cody Simmons: look, it is a bit larger, it looks a bit different, but it doesn't have irregular borders, it doesn't have odd colors in it, so it doesn't have like the classic signs of melanoma. That being said, melanomas can often be subtle and and and challenging to diagnose. So I'm not confident saying it's benign because I'm not a dermatologist, right? I'm your family doctor.
we could go ahead and refer you to dermatologist, but you know, I know you're a busy guy, it's hours off work, a $50 to $100 copay, many areas is a couple months wait time. the good news is we just got this new device that was cleared by the FDA. There's many published studies, and two of them show head to head it's as accurate as in-person dermatologists. Gary Kadi: It edited accurate different. Cody Simmons: It's called dermasensor, and it works by non-invasively scanning the skin lesion Gary Kadi: I think that you have to leave them. Cody Simmons: to see are there any signs of cancer within the cells beneath the surface of the
Gary Kadi: Got it. Yeah. Yeah. Cody Simmons: So I'm gonna go ahead here and touch the screen and wakes up. That's a calibration step, just making sure nothing's blocking Gary Kadi: I'll take the back in that. Got it. Cody Simmons: the probe tip because the device works by emitting light and detecting what comes back. There's a spectrometer here in the device. So here Gary Kadi: Okay. Cody Simmons: I'll scan here. You can kind of see how the light flashes. Gary Kadi: yeah, so I yeah. Cody Simmons: Yeah, the video doesn't really catch it exactly, but it's almost like a ballpoint pen tip with like a little flashlight coming out, but a very yeah, Gary Kadi: Yeah. Yeah, we saw a flash. Cody Simmons: it's a it's a xenon lamp. It's pulsing hundreds
of different wavelengths, right? We see in three wavelengths. This is pulsing hundreds of different wavelengths. And so it's assessing the same things that a pathologist will look at under a microscope. For example, if cells have enlarged nuclei, they're gonna absorb more light, more photons at certain wavelengths. So that's what the spectral curves that result from this, the inventor, be you, Professor Irving Biggio, he can like read the curves. Like, yeah, this has enlarged nuclei. There's more presence of condensed chromatin in this one. It looks like the,
Carotinocytes are more dense and like because he knows what features correspond to what wavelengths and levels. So, okay, great. So, so then it gave me an error message because it knows I'm not holding it up to the lesion. So we have some Gary Kadi: Got it. Cody Simmons: cool usability. So it's like, put it on the lesion, idiot. Gary Kadi: Nice. Cody Simmons: so go ahead and take five different tissue samples. Each one is measuring Gary Kadi: Okay. Cody Simmons: about a millimeter tissue non-invasively, and Gary Kadi: Yeah. Cody Simmons: I'm picking it up, putting it down in different parts of the mole. The same way a pathologist Gary Kadi: Okay. Cody Simmons: will look at different parts of the biopsy tissue under
microscope. Right? So kind of sampling different. And now the Gary Kadi: Got it. So it's really the same thing. Yeah. Cody Simmons: FDA approved algorithms processing the data to see is there any cancer risk. Nope. Monitor. So monitors Gary Kadi: Got it. Yep. Cody Simmons: the negative result. That's like zero. A positive Gary Kadi: Right. Cody Simmons: result to investigate further says, okay, there's some chance of cancer, but this scale Gary Kadi: Yep. Yep. Got it. Cody Simmons: on a one to ten scale. And the likelihood of cancer. For monitor, depending which study you read, was 97 to 100%. the likelihood of cancer for positive results investigate further, one to 10. And
the pivotal study with over a thousand patients, 22 study centers led by Mail Clinic, was 6% for a score of one and 61% for score of 10. So a 10-fold difference in cancer likelihood. And you do this quick non-invasive process, and now you as a doctor, you know where the mole falls on that risk continuum. Gary Kadi: That's fantastic. Congratulations and thanks for sharing that. That is that is really magnificent. And and it makes it doable for a a physician who has, you know, PCP, who has very few you know, doesn't have a lot
of time. That was clear that that was pretty quick and and and knowing it's accurate and approved by FDA is is rock solid. So I have two more questions for you. And man, I can't believe it. We only have five minutes left. Cody, what the heck happened? Cody Simmons: wow. Okay. Gary Kadi: So I want to make sure we the audience here is these two because when I analyzed the questions I thought would be interesting to our audience in addition to your great you know device, two questions I have. One is on trust. You know, you're a bioengineer, you're selling to physicians. What did you have to learn about
earning trust from people with people that have more training than you? Like what did you learn about about this earning of trust? Cause if you didn't earn trust through this whole process, You know, this wouldn't come to fruition. It never would have come to reality in a in a company. Give us a few insights that you learned along the journey of like how you learned how to build trust with people around you. Cody Simmons: Yeah, I mean I I think it's tough, right? 'Cause you have to strike that balance of kind of being a leader and, you
know, kind of showing you you can make this vision happen, but also people not thinking you're you're full of hot air. and Gary Kadi: Yeah. Cody Simmons: especially when you're an a younger entrepreneur and a first Gary Kadi: Yeah. Yeah. Cody Simmons: time entrepreneur, which I was both, it can be particularly, particularly tough. So I think for me, for me the is that there a noise coming through by the way, or can you hear me fine? Gary Kadi: Yeah, I hear a little bit. Yep. Cody Simmons: Okay. my headphones on. Gary Kadi: It Cody Simmons: For me, I think the key thing sorry. You want me to re answer this by the way or
Gary Kadi: no you can go right through. You're good. It wasn't that bad. I like the authenticity. Cody Simmons: you can't hear it anymore. Gary Kadi: Yeah, no, you're good. I can hear a little bit, but we can Cody Simmons: Okay, I'm on Gary Kadi: keep go Yeah, we can keep going. Cody Simmons: Okay, so so for me, the key thing I think and kind of mindset to have is is confident but humble. Gary Kadi: Yep. Yep. Cody Simmons: You know, think humility and the nice thing was, yeah, I kinda had a personal family history and involvement with skin cancer, but professionally, right? I wasn't a
Gary Kadi: Right. Right. Exactly. Cody Simmons: dermatologist, wasn't a primary care doctor, I had no sh so you know, so everything I learned was kind of osmosis from experts in the field, right? And I Gary Kadi: Yeah. Cody Simmons: and as an engineer in economics background was used to kind of just synthesizing and analyzing. So Gary Kadi: Right. Cody Simmons: I think that's, you know, especially when you're in a new area, you know, stay stay humble, stay open. But you also obviously have to have that level of confidence in you know, taking account a lot of feedback. We've, you know, talked to a lot of the
experts. Here's a various opinion, sometimes they differed, but Gary Kadi: But definitely. Cody Simmons: here's the best plan and here's why, and we're gonna be successful. Right. I think that's kind Gary Kadi: Yeah. Cody Simmons: of generally the the MO and And you know, you really gotta practice what you preach, right? There's we've seen other companies that have really tried to cut corners and and I we have not when it comes to clinical data, especially, right? You know, really robust Gary Kadi: Yep. Cody Simmons: studies, really upfront with the FDA, you know, multiple pre submission meetings before we did the studies and we do the studies,
you know, and and share all those results and We got grilled with questions for back and forth for many months. I got shingles during it. That was fun. yeah, yeah. Gary Kadi: boy. Cody Simmons: So very very long, intense process. But you know, at the day, at the end of the day, right, that that commitment to high quality studies and evidence and their trust in in Gary Kadi: Their tracks and technology that people are involved. Yep. Cody Simmons: the company and the people involved is part of their their decision making process, right? Cause they don't want to prove especially a first in class product for cancer for use by people who are not experts. Gary Kadi: Yep.
Cody Simmons: Right, there's a lot of reasons for them to be pretty concerned with that. Gary Kadi: Right. I think for a lot of reasons for them to be pretty concerned with that. especially after the full stock inventory to block all the whole bit of Cody Simmons: especially after the pulse oxymetry debacle had just unfolded. It was months after that the medical community was like, wait, pulse oxymetry isn't accurate on African Americans. That's a problem. Right. Gary Kadi: Yeah. Cody Simmons: Yeah. And so they directly told us kind of during the review, they're like, Yeah, we we do not want to prove something that we later find out doesn't work on certain ethnicities. Like that is Gary Kadi: Right. Cody Simmons: so you know, they they Part of the back and forths was, okay, we get the technical literature, and
also your studies don't suggest that there's any impact of device performance on skin of color, right? Because you're not assessing the visual appearance, you're assessing cellular Gary Kadi: Mm-hmm. Right. Cody Simmons: level information, but you don't have tons of cancers in darker skin types because they're way less common, right? So Gary Kadi: Mm-hmm. Yep. Cody Simmons: we won't restrict the device from use in darker skin types, but we want Gary Kadi: we want you to do post market survey on it. Cody Simmons: you to do post-market surveillance to actually collect more data and show that. Especially for melanoma. So that was kind of where things netted out with the FDA. Gary Kadi: Right. Cody Simmons: And and and a lot of companies get asked to do that and then
they just don't. They don't do the studies. So, you know, I think Gary Kadi: Right. Yeah, yeah, yeah. Cody Simmons: part of it was a trust, like, you know, given all the work we had done, we submitted six clinical studies to the FDA in total. Gary Kadi: I don't know, you know, we'd be Cody Simmons: And they're like, okay, you know, we we how this company operates and having gotten to know them over eight years of meetings, Gary Kadi: Right. Cody Simmons: you know, we believe they'll actually be able to, you know, conduct a study and that it's safe to to approve. Gary Kadi: And I I think there's one thing that you didn't mention that I've experienced with you is you're a man of your word. You showed up like ready to go. You were a minute, I think
you were a minute or two late. You acknowledged that you were late, like you're a man of your word. And, you know, through eight years of demonstrating integrity, personal integrity, also for me in my experience, that's probably why you're very successful in what you do as well. Just in my own experience of your your trust, the trust that you built with me. So yeah, pretty cool. Cody Simmons: I appreciate that. Yeah, I'm not I'm not great at always being on time, but I always just so much going on, but I always make sure to apologize when I'm not 'cause yeah. Gary Kadi: Yeah, no, that's your man of your word. Like that's pretty that's that that little nuance. Somebody might just step over that. And my experience was like, and I had
to adjust my calendar and you you adjusted and we worked it out. So I just noticed you operate from a foundation of integrity. And I think that that's really powerful too, Cody. Cody Simmons: Thank you. Gary Kadi: Last here, you're welcome. Last question. Most founders underestimate this gap, I find. And I I'm gonna ask you this question. What broke first when you when you cleared to actually start selling? Like what was the what was the break Cody Simmons: Yeah. Gary Kadi: that happened for you when you started to scale? Cody Simmons: hmm. Yeah, I mean, well, so there's two I'll I'll cover two
quickly. Our first big issue, which ended up being a blessing in disguise, was we didn't have product supply. So we'd worked Gary Kadi: Mm. Cody Simmons: with kind of small local design firm doing the final miniaturization work and kind of small Gary Kadi: Right. Cody Simmons: batch manufacturing, but post COVID they lost some of their top engineers. They like went bankrupt. Ultimately Gary Kadi: They lost a five cars they like. Cody Simmons: they still owe us hundreds of thousands of dollars, actually. Gary Kadi: wow. Cody Simmons: so yeah, so that's fun. so Gary Kadi: Yeah. Cody Simmons: we switched to a bigger firm, but that wasn't ready Gary Kadi: Probably that wasn't ready in my following threat. Okay. Cody Simmons: in time following clearance. So we didn't have devices at clearance. Of course, sales team commercially were, you know, there's frustration
and in retrospect, such a so so helpful that we had not just a few months before FDA clearance, but time post FDA clearance to actually prepare, start initial discussions, you know, lock in some of the sales processes, training material for customers, et cetera. to actually when we start delivering devices make that successful. so I think that's Gary Kadi: Mm-hmm. Cody Simmons: something, since I know a lot of your audience as entrepreneurs, Gary Kadi: Yeah. Right. Right. Right. Cody Simmons: to really be thoughtful about is just because you can hit
go from a regulatory standpoint, do you actually want to? Right? so kind of how much time does the team the need and and this one isn't isn't new, but when you hit go That's also when the clock starts in terms of investors counting. How are they doing sales-wise? Right. And I think that's Gary Kadi: Right, right. Right. Cody Simmons: the other challenge. Like that, like I used to be so I was frustrated. I'm like, man, we've got to get FDA clearance in 2023. Right. Like it'll be so Gary Kadi: Yeah. Cody Simmons: embarrassing if it's and now I'm like, thank God we didn't get clearance in 2023. Cause now when
Gary Kadi: Right. Cody Simmons: we talk about, how many years have you been on the market and what are your sales levels and how you ramp it up? Like, yeah, we got clearance in 2024. First sale was mid that year. You know, we're we're ramping up quickly, blah, blah, blah. Right. If like, yeah, clearance twenty twenty three, it kind of puts an extra almost expectation on, you know, where sales levels and partnerships and stuff should be. so I think that was the next one in terms of what broke was quickly realizing we can't do this alone. There's three hundred thousand primary care physicians at a hundred and forty thousand locations in the US. How the hell do you effectively
scale to those? I mean, you can't. and you know, as a small startup, like, yeah, we we've ultimately raised over forty million dollars, but the kind of round to commercialize was a bit over ten million. Like you you can't hire two hundred sales reps with that. Right. Gary Kadi: Right. Cody Simmons: So, you know, for us it was like, okay, digital marketing, the majority of our sales comes through that, you know, leads generated by digital marketing. you know, our sales reps obviously did some of their own outreach, you know, through email and LinkedIn and other other avenues.
But what we're announcing, actually, sorry, this podcast will be aired in couple weeks. So what we announced recently was Gary Kadi: Okay. Cody Simmons: some major channel partnerships. Gary Kadi: Okay. Cody Simmons: one is with one of the largest distributors in the country. They have hundreds of sales reps, call on Gary Kadi: Great. Cody Simmons: tens of thousands of primary care locations. so they're very excited about you know adding this Time magazine best invention now, you know, Gary Kadi: Yeah. Cody Simmons: automated skin cancer scanner, right, to sales reps. Bag and we're also working with a contract sales force called MTMC,
MedTech Medicare, which has over 100 sales reps and many of Gary Kadi: Yep. Great. Cody Simmons: them are focused on primary care. also a reseller to the VA called Medical Place that's been selling to them for over 40 years. We're excited Gary Kadi: Nice. Cody Simmons: about that partnership. And lastly, I can't name them, but one of the largest health systems in the country, really in the world, that employs or or health networks that employs tens of thousands of primary care doctors. So yeah, so I think Gary Kadi: That's great. Yep. Cody Simmons: with those kind of partnerships in place now we're really well positioned to the scale.
Gary Kadi: Yeah, no, it's fantastic. Congratulations. And if you know, outside of this, if you wanted to have a conversation about distribution and and sales and marketing, I I have a lot of channels that I'm I've been over the years connected to. If you wanted to do a separate Cody Simmons: Okay. Yeah, no, you've had a lot of success in in this kind of world. So no, it'd Gary Kadi: Yeah, this is my jam. Yeah, if you wanna do Cody Simmons: be great to chat. Maybe we'll have a call. Yeah, with Gary Kadi: that. Yeah, yeah, yeah. If you wanna if you Cody Simmons: our SVP of sales. And and I forgot to mention, yeah, we we also just launched a so we raised sixteen million in the series B and we just opened up because we have so many,
you know, patients and customers and you know, I don't know six thousand LinkedIn followers now. And a lot of them often ask, Hey, can we invest? Like how can we get more involved? We love what you're doing. So we just on the back of our series B put up a WeFunder campaign. Gary Kadi: Great. Cody Simmons: that's also, you know, if there's listeners interested, you know, we've had everywhere from the $500 to $100,000 investment so far. We've raised well this podcast will be a little delayed, but $850,000 in the first few weeks. so we're excited, you our Gary Kadi: Congratulations. Cody Simmons: whole thing's right, democratizing access to effective skin cancer checks. So kind of
Gary Kadi: Yep. Cody Simmons: also democratizing access to who can invest in that, not just, you know, VCs and family offices. Gary Kadi: Great. Cody Simmons: Made a lot of sense for us. Gary Kadi: for sure. I love that. so how how could someone get in touch with you? just let's make sure we we get that in our notes here. Cody Simmons: Sure, yeah. LinkedIn I'm actually pretty responsive. so you Gary Kadi: Great. Cody Simmons: know, Cody Simmons Dermosensor I'd pop right up. and also my email, Cody.simmons Gary Kadi: Yep. Cody Simmons: at dermasensor.com, also works well. Gary Kadi: Great. Great. Well, Cody, this has been extraordinary. I thank you for
taking the time out. Thank you for creating such a great product and a company that is gonna really change people's lives. And we're very grateful to have you on the Delegate podcast. Cody Simmons: Gary, my pleasure. And yeah, my our our marketing team, you know, we get hit with kind of podcast invites all the time, one or two a week. And the marketing team, Gary Kadi: Yep. Cody Simmons: when I forwarded yours was very excited. They said, Yeah, no, this is really impressive. Gary Kadi: Yeah, but I'm talking about Great. Cody Simmons: the the podcast folks and guests he has on and also the audience. So you you definitely gotta do it. So thank you for including me.
Gary Kadi: You bet. Thanks. And we'll get this out to you and have a great day and keep making a difference for people. And stay out of the sun, Cody Simmons: Good. Thanks, Gary. Gary Kadi: me. I'll say that to myself. Have a great one. Thanks, Cody. Bye now.
What would your week look like if the work that used to take ten hours took one? Gus sits down with Jason Hubler, founder of ESS Business Services in York, Pennsylvania, and President of the Pennsylvania Business...
What if the work that used to fill your whole day could shrink to a couple of hours, and the time you got back actually belonged to you? Gus sits down with Lord Ian Ruiz, video editor at delegAIte, for a special Talking...
What if the best way to stand out in an inbox full of AI is to show up as a human? Gus sits down with Abe Dearmer, CEO of Sendspark, an AI video platform owned by Xenon Partners, calling in at 5 AM from Australia. Abe...
What happens when everyone in your company is already using AI and nobody has written down the rules? I sit down with Richard Schreiber, who has been in legal operations since 1983 and spent 25 years leading major...
What if the skills that help you understand an autistic child are the same ones that close more deals? Megan Killion and I share a lot. We both grew up on Cape Cod, in Dennis, and Megan, like my son, grew up with autism...